CA
NZ
UK
AU
IND
US
Invivyd, Inc. (Nasdaq: IVVD) announced that its monoclonal antibody PEMGARDA® (pemivibart) has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. The update identifies PEMGARDA as a potential pre-exposure prophylaxis (PrEP) option against COVID-19 for patients …
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) presented new long-term data from its Phase 2 TELLOMAK trial evaluating lacutamab in Sézary syndrome (SS) and mycosis fungoides (MF) at the ASCO 2025 Annual Meeting. The findings, as of the October 17, 2024 data cut-off, …
Sanofi (NASDAQ: SNY)is a global healthcare company focused on developing medicines and vaccines, with an emphasis on innovation, sustainability, and social responsibility. They company has announced a definitive agreement to acquireVigil Neuroscience, Inc. (NASDAQ: VIGL), a clinical-stage biotechnology company focused on treatments for neurodegenerative …
Polyrizon Ltd. (Nasdaq: PLRZ), a biotech firm focused on intranasal hydrogel technologies, has released findings from recent ex vivo studies demonstrating key performance characteristics of its proprietary formulation. The tests focused on two critical aspects: surface coverage and mucoadhesion—both fundamental to the platform’s intended …
Weave (NYSE: WEAV)has completed its acquisition of TrueLark, an AI-based front-desk automation and receptionist platform, advancing its broader strategy of integrating artificial intelligence into healthcare communications. The deal represents a step forward in Weave’s focus on expanding its offerings for small and medium-sized healthcare …
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a company specializing in the development and commercialization of medicines targeting infectious diseases, announced its financial results for the first quarter ended March 31, 2025. The results highlighted continued revenue growth and product traction, particularly in the …
CureVac N.V. (NASDAQ: CVAC), a global biopharmaceutical leader in messenger RNA (mRNA) innovation, has secured another key legal victory in its ongoing patent litigation against BioNTech SE. The European Patent Office (EPO) has upheld the validity of CureVac’s European patent EP 4 023 755 …
AbCellera Biologics Inc. (Nasdaq: ABCL) has received a No Objection Letter (NOL) from Health Canada, authorizing the company to proceed with a Phase 1 clinical trial for its investigational drug candidate ABCL635. The study is focused on addressing moderate-to-severe vasomotor symptoms (VMS), commonly referred …
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company focused on treating Obstructive Sleep Apnea (OSA), announced its financial results for the first quarter of 2025, reporting revenue of €1.1 million, down from €1.2 million in the same quarter last year.
RadNet, Inc. (NASDAQ:RDNT), a national leader in outpatient diagnostic imaging has reported its financial results for the first quarter of 2025, tempered by weather-related disruptions. At the same time, the company has raised its full-year financial guidance and made strategic moves to enhance its …
Please wait processing your request...